바이오다인

314930KOSDAQ의료용 기기 제조업

48.3 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Slightly down 4.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioDain develops, manufactures, and sells liquid-based cytology (LBC) equipment and cancer diagnostic kits, leveraging its proprietary Blowing Technology to enhance diagnostic accuracy and usability. The company exports its products to 13 countries, including Japan, the U.S., and Europe, and collaborates with Roche to develop the VENTANA SP400 device, expanding its global market presence.

Number of Employees

23people

Average Salary

39.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

373.79Industry Average 21.510.0Point

17.4x industry avg (risky)

PBR

7.32Industry Average 1.380.0Point

5.3x industry avg (risky)

ROE

1.95Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

—Industry Average 11.654.0Point

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲31.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲76.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
로슈, AI 병리 전환 본격화…바이오다인 기술 적용된 핵심 장비 역할....
로슈의 AI 병리 기술 도입으로 바이오다인의 핵심 장비 활용이 확대되어 주가 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 10,840Won52-week high 16,68052-week low 9,660

1-month return2.0Point

1m -4.75% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
Neutral분기보고서 (2026.03)2026-05-15
Neutral기업설명회(IR)개최2026-05-15
Neutral주식등의대량보유상황보고서(일반)2026-05-15